$331 Million is the total value of RTW INVESTMENTS, LP's 36 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 125.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $64,275,000 | +39.1% | 948,286 | +13.9% | 19.42% | +23.1% |
| AVXS | Buy | Avexis Inc | $34,039,000 | +87.9% | 825,980 | +73.4% | 10.29% | +66.2% |
| AGEN | Buy | Agenus Inc | $29,737,000 | +202.3% | 4,141,644 | +70.5% | 8.99% | +167.4% |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $18,542,000 | +191.9% | 4,204,579 | +88.0% | 5.60% | +158.1% |
| New | Atara Biotherapeutics Inc. | $9,799,000 | – | 458,113 | +100.0% | 2.96% | – | |
| ARWR | New | Arrowhead Pharmaceuticals Inc | $8,208,000 | – | 1,116,777 | +100.0% | 2.48% | – |
| HRTX | New | Heron Therapeutics Inc | $6,664,000 | – | 386,787 | +100.0% | 2.01% | – |
| VIVE | Buy | Viveve Medical Inc | $6,060,000 | +81.4% | 839,274 | +3.0% | 1.83% | +60.5% |
| CORI | Buy | Corium International Inc | $5,888,000 | +98.9% | 1,045,747 | +22.6% | 1.78% | +76.0% |
| IVTY | Buy | Invuity Inc | $5,390,000 | +150.2% | 392,838 | +73.8% | 1.63% | +121.3% |
| MDCO | New | Medicines Co | $4,642,000 | – | 123,000 | +100.0% | 1.40% | – |
| TCMD | New | Tactile Systems Technology Inc Cmn | $4,256,000 | – | 227,599 | +100.0% | 1.29% | – |
| JJOFF | Buy | Barclays Bank Plcetn djubscoffe38 | $4,018,000 | +25.8% | 180,500 | +25.2% | 1.21% | +11.3% |
| OXFD | New | Oxford Immunotec Global PLC | $2,963,000 | – | 235,900 | +100.0% | 0.90% | – |
| NVAX | New | NOVAVAX INCcall | $996,000 | – | 4,787 | +100.0% | 0.30% | – |
| SRTS | New | Sensus Healthcare Inc Cmn | $773,000 | – | 125,700 | +100.0% | 0.23% | – |
| BOLD | New | Audentes Therapeutics Inc | $356,000 | – | 20,000 | +100.0% | 0.11% | – |
| ABEO | New | Abeona Therapeutics Inc | $116,000 | – | 19,391 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-11-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.